Recent studies have confirmed the survival benefit of ipilimumab (a monoclonal antibody that targets CTLA-4) in patients with advanced melanoma [27] and non-small-cell lung cancer [28]. Here, CTLA4 is linked to non-small cell lung carcinoma.